|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01069432 |
|
Date of registration:
|
15/02/2010 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
|
|
Scientific title:
|
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia |
|
Date of first enrolment:
|
May 2010 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
https://clinicaltrials.gov/show/NCT01069432 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Christopher H Lowrey, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Dartmouth-Hitchcock Medical Center |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients undergoing routine blood draws as part of their ongoing follow-up care for
CLL at the Norris Cotton Cancer Center of DHMC.
- Normal donors who have no history of active or prior hematologic malignancy.
Exclusion Criteria:
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted
antibody therapy for their CLL, other hematologic malignancy or other disease process
within the past 2 months are excluded. Use of intravenous immunoglobulin (IVIg) is not
a reason for exclusion.
- Normal donors who have a history of steroid use, immunosuppression therapy or
autoimmune disease are excluded.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Lymphocytic Leukemia
|
|
Intervention(s)
|
|
Other: No Intervention
|
|
Primary Outcome(s)
|
|
To identify the genes that are differentially expressed at the polysomal RNA and protein levels in human patient CLL cells (compared to normal donor lymphocytes) using high-throughput microarray approaches.
[Time Frame: 2 Years]
|
|
Secondary Outcome(s)
|
|
To determine whether the novel candidate genes from Specific Aim 1 have potential roles in CLL. (Note: Specific Aim 2 does not involve human subjects research).
[Time Frame: 2 Years]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|